The patented Safe-2-Dose™ Integrated Dosing Container is the next generation Infants elixir dispenser providing enhanced medication dosing accuracy and user convenience. The caregiver need only disabl
At Asepsis our goal is to develop and promote safer more accurate medicinal delivery devices for institutions, patients and relief organizations. Our company is committed to creating affordable innovative products that create higher standards of living for patients afflicted with multiple illnesses.Asepsis is committed to being a Good Corporate Citizen of the United Nations Global Compact, the world’s largest corporate citizenship initiative. The compact calls on corporations and other shareholders to support and uphold key principles in the areas of:
- Human Rights
- Labor
- Environment
- Anti-Corruption
Research and Development
We promote a safe workplace with a company philosophy that promotes individual innovation to be advanced through various scientific and mechanical disciplines. We recognize and consider the balance of ethical issues when it comes to the research and development of our products.
Philanthropic Engagement
Our company is committed to forging strategic relationships with NGO and Government organizations to position our advanced products in affected regions worldwide.
Protecting the Environment
We strive to make the most efficient use of recycled and natural products thereby minimizing the environmental impact of our activities.
Ethics, Governance and Compliance
At Asepsis we are committed to create a company of respect through promoting a culture of integrity throughout our company network, partners, production and distribution. At Asepsis we continuously strive to advance sound integral fundamental rules and principals of ethical business conduct.
Latest News
Asepsis Announces The Grant Of Mexico Patent No. 384,129
Asepsis Medical Technologies® is proud to introduce the latest addition to the Calibrated Drug Delivery™ (CCD) platform, the Multi-Dose Safe-2-Dose® syringe. The Multi-Dose Safe-2-
Asepsis Announces the Grant of Canadian Patent No. 3,006,218
Asepsis Medical Technologies® is proud to announce their latest Canadian Patent Grant 3,006,218 of August 24, 2021 – for the multi-dose oral Dose-2-Weight Syringe®. The Dose-2-Weight Sy
Asepsis announces the US Patent Grant 11,058,606
Asepsis Medical Technologies announces the USPTO issuance of Patent Application Number 11,058,606 for its Safe-T-Fuse™ drug infusion system. The Safe-T-Fuse™ is an industry unique infusion contai
Asepsis Announces the Grant of Mexico Patent MX/a/2017/012034
The Safe-T-Syringe® is designed to deliver the highest standard of patient care via syringe. Its medication calibrated indicia provide enhanced accuracy, convenience and safety through-out preparation
Asepsis Announces the Grant of U.S. Patent 10,857,299
Asepsis Medical Technologies® is proud to introduce the latest addition to the Calibrated Drug Delivery™ (CCD) platform, the Multi-Dose Safe-2-Dose® syringe. The Multi-Dose Safe-2-Dose® syringe provid
Asepsis Announces the U.S. Patent Grant No. 10,625,026
Asepsis Medical Technologies announces the U.S. Patent Grant for the Momenta-Dose™ forcé actuated injection device. The Momenta Dose™ is designed to administer rapid small volume subcutaneous or intra